MCF7, T47D, and ZR75–1 parental (P) cells were cultured as previously described (4 (link)). The EndoR cell derivatives [resistant to long-term estrogen deprivation (EDR), to tamoxifen (TamR), and to fulvestrant (FulR)] were established as previously described (4 (link),5 (link)). To generate resistant derivatives to palbociclib (SelleckChem), MCF7 P, MCF7 EDR, T47D P, and T47D EDR cells were exposed to progressively increasing doses of palbociclib up to 1 μM. T47D P-LM and T47D P/PalboR-LM were cultured and developed as described previously (6 (link)). All cell lines were authenticated at the MD Anderson Characterized Cell Line Core Facility, and were tested to be mycoplasma-free by MycoAlert™ Mycoplasma Detection Kit (Lonza). Because T47D P-LM and T47D P/PalboR-LM were grown in a different media from MCF7 P, MCF7 EDR, T47D EDR and their PalboR derivatives, all parallel molecular analyses were done independently.